IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.
A specific genetic mutation in brain tumors predicts which patients will respond to oncolytic virus therapy, enabling precision treatment selection.
IDH1-R132H mutation in gliomas creates a dual vulnerability to oncolytic HSV-1 therapy by upregulating the viral entry receptor Nectin-1 and suppressing interferon signaling through DNA hypermethylation, with combination TIGIT blockade further enhancing efficacy in immunocompetent murine models. IDH1-R132H is proposed as a predictive biomarker for response to CAN-3110 oncolytic virotherapy in high-grade gliomas, a precision approach for a rare cancer with poor prognosis.
What the study was
- Study design
- Preclinical (murine glioma model) + in vitro mechanistic
- Population
- IDH1-R132H-mutant diffuse glioma models (murine + human cell lines)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nat Commun
Why it surfaced
Unsolicited find: novel precision oncology concept — IDH mutation as biomarker for oncolytic virotherapy sensitivity in glioma, with mechanistic clarity from Harvard/Brigham group. Preclinical only; score capped at 5.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.